Merck Expands Singapore Lab to Bolster APAC Biosafety Testing

Merck Life Science is expanding its BioReliance laboratory in Singapore to meet growing demand for biosafety testing services in the Asia-Pacific region.

The expansion will allow Merck to provide more advanced local contract testing services, including cell line characterization and good manufacturing practice (GMP)-based next-generation sequencing (NGS) capabilities.

This is part of Merck's broader investment in its Asia-Pacific biopharmaceutical testing capabilities.

The Singapore facility will also offer advanced molecular testing services using Merck's proprietary Blazar platform.

Biosafety testing is a key aspect of biopharmaceutical development and manufacturing, helping companies assess product safety and meet regulatory requirements.